Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UNIMED's MARINOL NDA WILL BE RESUBMITTED

Executive Summary

UNIMED's MARINOL NDA WILL BE RESUBMITTED after the company meets with FDA to discuss the agency's withdrawal of an "approvable letter" for the drug, the company announced in a Nov. 7 press release. Unimed President and CEO Paul Bollenbacher said that the company plans "to move quickly to resubmit the application and satisfy all of their [FDA's] requirements." The company said FDA withdrew the July 31 "approvable letter" for Marinol (dronabinol-THC) because "of certain deficiencies related to two clinical tests which were viewed as pivotol to the agency's ability to judge Marinol as safe and effective." Bollenbacher commented that he was "absolutely dumbfounded by the FDA's decision, since the company has submitted additional data, including labeling information, to the FDA in August." Unimed filed an NDA for Marinol in June 1981. The drug, used to control vomiting and nausea associated with chemotherapy, has been distributed by the Natl. Cancer Institute (NCI) for the last four years. Approximately 800 hospitals, 2,600 doctors, and 25,000 cancer patients have participated in NCI's free THC distribution program, Unimed stated. Unimed has at least two other drugs in clinicals, an anticancer agent Spiro-32 spiro-germanium), and Serc (betahistamine HCI) for the treatment of cerebrovascular disease. The company said it has not been pursuing studies of its L-alpha-acetyl-methadol, a long-acting drug for use in controlled withdrawal from morphine-type addiction, "because of some problems with safety raised by FDA."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel